Treatment-resistant Depression
Jul 21, 2026
Novartis Secures FDA Traditional Approval for Fabhalta in Primary IgAN; GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough; Merck Secures FDA Approval for LIPFENDRA; Innovent Reports Positive Phase II Results for Soficinib in Vitiligo; Lilly Signs Deal to Acquire AtaiBeckley for Mental Health Therapies
Novartis Wins FDA Traditional Approval for Fabhalta to Treat Primary IgAN Novartis announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta (iptacopan) for slowing the progression of kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) wh...
Read More...
Feb 21, 2025
J&J’s SPRAVATO Achieves Milestone with Monotherapy Approval in Depression Treatment
Johnson & Johnson’s SPRAVATO, which is already on track to become a blockbuster drug, has received a significant boost with the FDA’s approval for its use as a standalone treatment for major depressive disorder (MDD). Initially approved in 2019, SPRAVATO was authorized for use alongside an oral antidepressant i...
Read More...
Feb 14, 2022
How to Cure Treatment-resistant Depression?
Treatment-resistant Depression (TRD) typically refers to inadequate response to at least two antidepressant medications used for a sufficient length of time at an adequate dose with an adequate affirmation of treatment adherence. Treatment-resistant Depression is a relatively common occurrence in clinical practice,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
